Johnson & Johnson (JNJ) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its Tecnis PureSee intraocular lens (IOL), giving eye surgeons a new lens option for use in ...

Johnson & Johnson (NYSE: JNJ) announced that it received FDA approval for its Tecnis PureSee intraocular lens (IOL) for cataract surgery.

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients ...

The FDA approved the Tecnis PureSee IOL, an extended depth of focus IOL for cataract surgery, according to a press release ...

Dr. Greenstein answers the question: 'Types Of Intraocular Lens Implants?' Aug. 24, 2009— -- Question: What are the different types of intraocular lens implants and how do I decide on which one ...

The purpose of this study was to examine the preoperative factors and postoperative outcomes following intraocular lens (IOL) exchange for high myopia in pseudophakic children. A total of 15 eyes were ...

Consecutive patients with MA50 IOLs placed in the sulcus at the University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA, from 1997 to 2012 were identified. Inclusion criteria included patients ...

—There is no perfect intraocular lens, but matching a patient with the lens that best meets their needs can help reduce postoperative dissatisfaction. Reviewed by Sarju Patel, MD, MPH, MSc, Director ...

Abbott announced that the Food and Drug Administration (FDA) has approved the Tecnis Symfony Intraocular Lenses for the treatment of cataracts. Abbott announced that the Food and Drug Administration ...

Intraocular lenses (IOLs), implanted in the eye as treatment for cataracts or myopia, are a growing global market in an ageing population, one estimated to be worth more than $4.5 billion by 2022.

Using sulcus lenses in cases of intraoperative complications.Inspecting and monitoring the lens during implantation to recognize any defects.

According to the company, the lens is the first and only FDA-approved EDOF IOL in the US without a warning regarding loss of contrast sensitivity. Johnson & Johnson announced that the US Food and Drug ...